BeiGene
BGNE
#942
Rank
A$32.35 B
Marketcap
$290.86
Share price
-3.00%
Change (1 day)
-6.22%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Market capitalization of BeiGene (BGNE)

Market cap: A$32.35 Billion

As of November 2024 BeiGene has a market cap of A$32.35 Billion. This makes BeiGene the world's 942th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of BeiGene from 2016 to 2024

End of year Market Cap

Year Marketcap Change
2024A$32.35 B11.24%
2023A$29.08 B-15.63%
2022A$34.47 B-9.07%
2021A$37.91 B21.33%
2020A$31.25 B112.67%
2019A$14.69 B24.2%
2018A$11.83 B107.54%
2017A$5.70 B241.11%
2016A$1.67 B

End of Day market cap according to different sources

On Nov 14th, 2024 the market cap of BeiGene was reported to be:

A$34.09 Billion
by Yahoo Finance info icon info icon
A$34.09 Billion
by CompaniesMarketCap info icon info icon
A$31.96 Billion
by Nasdaq info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
A$32.42 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
A$1.68 B-94.80%๐Ÿ‡บ๐Ÿ‡ธ USA